Biotech RadarJobs updated

COMPANY

Sound Pharmaceuticals, Incorporated

HQ: Seattle, WA source · soundpharma.com ↗

Clinical Phase 3

Also known as Sound Pharmaceuticals · 12 sources

Location: Seattle, WA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Meniere's Disease Hearing Loss Ototoxicity Covid19 Coronavirus Coronavirus Infection Corona Virus Infection Meniere Disease Ménière Ménière's Disease Cochlear Trauma Temporary Auditory Threshold Shift Lung Cancer Head and Neck Cancer Tinnitus Neuropathy Noise Induced Hearing Loss Ebselen SPI-1005

12Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: SPI-1005 in Adults Receiving Cochlear Implant source ↗
  2. Trial start Phase 2: SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss source ↗
  3. Trial start 2: A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss source ↗
  4. Trial start Phase 3: SPI-1005 for the Treatment of Meniere's Disease (Open Label) source ↗
  5. Trial start Phase 3: SPI-1005 for the Treatment of Meniere's Disease source ↗
  6. Trial start Phase 2: SPI-1005 Treatment in Moderate COVID-19 Patients source ↗
  7. Trial start Phase 2: SPI-1005 Treatment in Severe COVID-19 Patients source ↗
  8. Trial start Phase 2: SPI-1005 for the Treatment of Patients With Meniere's Disease source ↗
  9. Trial start Phase 2: SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity source ↗
  10. Trial start Phase 1/Phase 2: Study to Evaluate SPI-1005 in Adults With Meniere's Disease source ↗
  11. Trial start Phase 2: Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift source ↗
  12. Trial start Phase 1: Study to Evaluate the Safety and Pharmacokinetics of SPI-1005 source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 12

RecordTitlePhaseStatusStartPrimary completion
NCT04677972SPI-1005 for the Treatment of Meniere's DiseasePhase 3CompletedAug 2, 2022Sep 19, 2023 (actual)
NCT02819856SPI-1005 for Prevention and Treatment of Tobramycin Induced OtotoxicityPhase 2CompletedJul 21, 2017Apr 7, 2023 (actual)
NCT06859788SPI-1005 for the Treatment of Meniere's Disease (Open Label)Phase 3Active, not recruitingOct 29, 20252026-12 (estimated)
NCT02603081Study to Evaluate SPI-1005 in Adults With Meniere's DiseasePhase 1/Phase 2Completed2015-122017-08 (actual)
NCT04483973SPI-1005 Treatment in Severe COVID-19 PatientsPhase 2CompletedAug 27, 2021May 5, 2023 (actual)
NCT06340633SPI-1005 in Adults Receiving Cochlear ImplantPhase 2Recruiting2026-122026-12 (estimated)
NCT01444846Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold ShiftPhase 2Completed2011-092013-12 (actual)
NCT01451853SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing LossPhase 2Withdrawn2026-062026-06 (estimated)
NCT02779192A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss2Withdrawn2026-062026-06 (estimated)
NCT04484025SPI-1005 Treatment in Moderate COVID-19 PatientsPhase 2Enrolling by invitationOct 12, 2021Dec 31, 2023 (estimated)
NCT03325790SPI-1005 for the Treatment of Patients With Meniere's DiseasePhase 2CompletedSep 28, 2017Apr 30, 2019 (actual)
NCT01452607Study to Evaluate the Safety and Pharmacokinetics of SPI-1005Phase 1Completed2006-052006-08 (actual)
Feedback